- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.24 | AIM WINNERS & LOSERS: Ondine Biomedical rises, Proton Power declines | 1 | Alliance News | ||
| 30.12.24 | Ondine enrols first patient in phase three clinical trial | 1 | Sharecast | ||
| 30.12.24 | Ondine Biomedical begins Phase 3 trial for infection prevention | 8 | Investing.com | ||
| 30.12.24 | Ondine Biomedical - Ondine recruits first patient for US Phase 3 trial | 1 | RNS | ||
| 17.12.24 | Ondine Biomedical to start phase three Steriwave clinical trial | 1 | Sharecast | ||
| 17.12.24 | Ondine Biomedical - Ondine commencing US Phase 3 clinical trial | - | RNS | ||
| 25.11.24 | Ondine Biomedical - Notification of Major Holdings | - | RNS | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 22.11.24 | Ondine Biomedical - Notification of Major Holdings | - | RNS | ||
| 22.11.24 | Ondine Biomedical directors update shareholdings post-fundraising | 1 | Investing.com | ||
| 22.11.24 | Ondine Biomedical - Director Holdings | - | RNS | ||
| 18.11.24 | Ondine Biomedical - NOTIFICATION OF MAJOR HOLDINGS | - | RNS | ||
| 15.11.24 | Ondine Biomedical - Final Result of Fundraise & TVR | - | RNS | ||
| 14.11.24 | Ondine Biomedical - Updated Result of Fundraise | - | RNS | ||
| 11.11.24 | Ondine Biomedical - Update on Private Placement and Placing | - | RNS | ||
| 08.11.24 | Ondine Biomedical: Life Sciences Company Raises C$16 Million | 2 | pulse2.com | ||
| 04.11.24 | Ondine Biomedical Inc.: Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial | 163 | Business Wire | Canadian life sciences company Ondine Biomedical announces that it is accelerating its final preparations for a Q4 2024 start to its key pivotal US Phase 3 trial following its recent successful raise... ► Artikel lesen | |
| 01.11.24 | Ondine Biomedical - Result of Fundraise | 1 | RNS | ||
| 01.11.24 | Ondine Biomedical shares climb as raises funds for US clinical study | 1 | Alliance News | ||
| 01.11.24 | Ondine raising £8.5m to fund US clinical trial | 1 | Sharecast | ||
| 01.11.24 | Ondine Biomedical - Proposed Fundraise | - | RNS |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 43,000 | +6,09 % | SpringWorks Therapeutics jumps amid takeover speculation | ||
| ADMA BIOLOGICS | 18,560 | 0,00 % | ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? | ||
| QIAGEN | 44,095 | -0,20 % | Qiagen schließt Partnerschaft mit Genomics England ab | DJ Qiagen schließt Partnerschaft mit Genomics England ab
DOW JONES--Qiagen schließt eine Partnerschaft mit Genomics England ab. Ziel ist es, die Durchführung der Generation Study zu unterstützen.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,390 | -1,64 % | 2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy | ||
| RECURSION PHARMACEUTICALS | 6,880 | -5,30 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen | |
| NUVALENT | 76,61 | -2,18 % | Nuvalent-Forschungschef verkauft Aktien im Wert von 197.853 US-Dollar | ||
| AVIDITY BIOSCIENCES | 29,460 | -1,44 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,020 | -12,25 % | Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell? | ||
| TEMPUS AI | 37,520 | +0,13 % | Tempus AI (NASDAQ:TEM) Trading Down 3.6% Following Insider Selling | ||
| KYMERA THERAPEUTICS | 38,170 | -5,80 % | Analysts Issue Forecasts for KYMR FY2029 Earnings | ||
| HARMONY BIOSCIENCES | 33,860 | -1,93 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,840 | -31,25 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen | |
| IMMUNOVANT | 23,480 | -0,70 % | Immunovant-Finanzchefin Eva Renee Barnett verkauft Aktien im Wert von 98.930 US-Dollar | ||
| BIONTECH | 119,40 | -0,50 % | BioNTech Aktie: Attraktive Dividenden erwartet! | Die BioNTech-Aktie startet dynamisch in das neue Jahr 2025 und verzeichnet einen bemerkenswerten Kurssprung von 108 Euro auf 112,30 Euro. Das Mainzer Biotechnologieunternehmen, das eine Marktkapitalisierung... ► Artikel lesen | |
| EVOTEC | 8,420 | -1,69 % | BMW, Evotec, Hensoldt, K+S, SMA Solar, ThyssenKrupp u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen |
Das Unternehmen ONDINE BIOMEDICAL INC CDIS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,083 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONDINE BIOMEDICAL INC CDIS finden Sie auf Wallstreet Online.
